INCYTE CORP director Paul J. Clancy received 265 shares of common stock as a fully vested restricted share award. The grant was made under Incyte's Amended and Restated 2010 Stock Incentive Plan in lieu of quarterly director retainer fees, pursuant to an election intended to comply with Rule 10b5-1. Following this compensation-related acquisition, he holds 23,741 shares directly, including 2,518 shares of common stock issuable from previously reported restricted stock units that have not yet vested.
Incyte Corporation reported that Board member Susanne Schaffert has resigned from its Board of Directors. She notified the company on March 26, 2026, and her resignation will be effective April 15, 2026.
The company stated that her resignation was not due to any disagreement regarding its operations, policies, or practices, and the Board expressed appreciation for her service since 2022.
Incyte Corp Schedule 13G/A amendment reports that The Vanguard Group holds 0% of Incyte common stock, with 0 shares beneficially owned as of the filing. The amendment explains an internal realignment effective January 12, 2026 that caused certain Vanguard subsidiaries to report ownership separately in reliance on SEC Release No. 34-39538.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026.
INCYTE CORP executive reports routine tax withholding share disposition. EVP, GM Dermatology US Matteo Trotta had 537 shares of common stock withheld at a price of $92.23 per share to cover tax obligations tied to previously granted restricted stock units. After this automatic withholding, he directly holds 14,882 common shares. Footnotes state that this figure includes 11,160 shares underlying restricted stock units that are not yet vested.
Incyte Corporation announced several executive leadership changes. Pablo J. Cagnoni was appointed President, Incyte and Global Head of Research and Development, adding broader enterprise-wide strategic and operational responsibilities while continuing to lead R&D. Steven H. Stein became Executive Vice President, Chief Medical Officer and Head of Late-stage Development, continuing to oversee late-stage programs in Hematology, Oncology and Immunology and Global Medical Affairs.
Mohamed Issa was appointed Executive Vice President and Head of U.S. Commercial, continuing to lead U.S. Oncology and taking on expanded responsibility for U.S. Immunology as these businesses are integrated into a single U.S. commercial organization. William J. Meury remains Chief Executive Officer and a member of the Board, while Matteo Trotta, Executive Vice President and General Manager, U.S. Dermatology, will leave Incyte following a transition period. The filing states there were no changes to compensation arrangements for the impacted executives in connection with these title changes.
INCYTE CORP President, R&D Pablo J. Cagnoni exercised stock options and then sold shares in a routine liquidity transaction. He exercised options to acquire 7,166 shares of common stock at $61.18 per share and 11,501 shares at $64.25 per share, totaling 18,667 shares. On the same day, he sold 18,667 common shares at an average price of $94.24 per share. After these transactions, his reported direct ownership was 234,800 common shares, which the notes state includes 229,661 shares underlying previously reported unvested restricted and performance stock units.
INCY reports a Form 144 notice for the sale of 18,667 shares of Common Stock via a stock option exercise on 03/17/2026. The filing lists proceeds of 1,759,101.55 and shows prior sales in the past three months associated with Pablo Cagnoni. The transaction is reported through Morgan Stanley Smith Barney LLC as broker-dealer.
Incyte Corporation reported that on February 27, 2026, the U.S. Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Zynyz (retifanlimab-dlwr) injection in metastatic non-small cell lung cancer in combination with platinum-based chemotherapy.
The FDA’s letter cited regulatory compliance inspection findings at Catalent Indiana, the third-party fill-finish facility referenced in the application, as the sole approvability issue. The FDA did not raise concerns about Zynyz’s efficacy, safety data in NSCLC, or the third-party drug substance manufacturer. Incyte is working with the FDA and Catalent Indiana to address the letter and support a potential resubmission.
INCYTE CORP President, R&D Pablo J. Cagnoni reported multiple equity transactions. On February 19, 2026, he exercised employee stock options into 13,093 and 5,575 shares of common stock at exercise prices of $61.76 and $61.18 per share, respectively, through derivative conversions.
He then executed an open-market sale of 18,668 shares of common stock at an average price of $100.91 per share. After these transactions, he directly owned 234,800 shares of common stock, plus remaining stock options, and had an additional 229,661 shares tied to unvested restricted and performance stock units.